Cargando…
Indoxyl Sulfate and Incident Peripheral Artery Disease in Hemodialysis Patients
Peripheral artery disease (PAD) is highly prevalent among patients with chronic kidney disease (CKD) and portends a very poor prognosis. Indoxyl sulfate has been shown to induce atherothrombosis and impaired neovascularization in uremic mice. However, there is no clinical evidence regarding the role...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693838/ https://www.ncbi.nlm.nih.gov/pubmed/33147880 http://dx.doi.org/10.3390/toxins12110696 |
_version_ | 1783614837985640448 |
---|---|
author | Lin, Ting-Yun Chou, Hsin-Hua Huang, Hsuan-Li Hung, Szu-Chun |
author_facet | Lin, Ting-Yun Chou, Hsin-Hua Huang, Hsuan-Li Hung, Szu-Chun |
author_sort | Lin, Ting-Yun |
collection | PubMed |
description | Peripheral artery disease (PAD) is highly prevalent among patients with chronic kidney disease (CKD) and portends a very poor prognosis. Indoxyl sulfate has been shown to induce atherothrombosis and impaired neovascularization in uremic mice. However, there is no clinical evidence regarding the role of indoxyl sulfate in PAD associated with CKD. We examined associations between indoxyl sulfate and incident symptomatic lower extremity PAD events as well as major adverse cardiovascular events (MACE) and all-cause mortality using Cox proportional hazards models in a prospective cohort of 200 hemodialysis patients free of PAD at baseline. Patients were considered as having PAD if they developed PAD symptoms confirmed by an ankle-brachial index with waveforms, duplex ultrasound or angiography, and/or major adverse limb events including revascularization and amputation. During a median follow-up of 6.5 years, 37 patients (18.5%) experienced incident symptomatic PAD. MACE occurred in 52 patients, and a total of 85 patients died. After adjusting for traditional risk factors for PAD, including age, current smoking, diabetes, and cardiovascular disease, indoxyl sulfate was significantly associated with the risk of PAD (hazard ratio (HR), 1.19 for every 10-μg/mL increase in indoxyl sulfate; 95% confidence interval (CI), 1.05–1.35). However, indoxyl sulfate was not associated with risk of MACE (HR, 1.00; 95% CI, 0.90–1.12) or death from any cause (HR, 0.98; 95% CI, 0.90–1.07). Indoxyl sulfate was associated with incident symptomatic PAD but not with MACE or all-cause mortality, suggesting that indoxyl sulfate toxicity may be unique to PAD among hemodialysis patients. |
format | Online Article Text |
id | pubmed-7693838 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-76938382020-11-28 Indoxyl Sulfate and Incident Peripheral Artery Disease in Hemodialysis Patients Lin, Ting-Yun Chou, Hsin-Hua Huang, Hsuan-Li Hung, Szu-Chun Toxins (Basel) Article Peripheral artery disease (PAD) is highly prevalent among patients with chronic kidney disease (CKD) and portends a very poor prognosis. Indoxyl sulfate has been shown to induce atherothrombosis and impaired neovascularization in uremic mice. However, there is no clinical evidence regarding the role of indoxyl sulfate in PAD associated with CKD. We examined associations between indoxyl sulfate and incident symptomatic lower extremity PAD events as well as major adverse cardiovascular events (MACE) and all-cause mortality using Cox proportional hazards models in a prospective cohort of 200 hemodialysis patients free of PAD at baseline. Patients were considered as having PAD if they developed PAD symptoms confirmed by an ankle-brachial index with waveforms, duplex ultrasound or angiography, and/or major adverse limb events including revascularization and amputation. During a median follow-up of 6.5 years, 37 patients (18.5%) experienced incident symptomatic PAD. MACE occurred in 52 patients, and a total of 85 patients died. After adjusting for traditional risk factors for PAD, including age, current smoking, diabetes, and cardiovascular disease, indoxyl sulfate was significantly associated with the risk of PAD (hazard ratio (HR), 1.19 for every 10-μg/mL increase in indoxyl sulfate; 95% confidence interval (CI), 1.05–1.35). However, indoxyl sulfate was not associated with risk of MACE (HR, 1.00; 95% CI, 0.90–1.12) or death from any cause (HR, 0.98; 95% CI, 0.90–1.07). Indoxyl sulfate was associated with incident symptomatic PAD but not with MACE or all-cause mortality, suggesting that indoxyl sulfate toxicity may be unique to PAD among hemodialysis patients. MDPI 2020-11-02 /pmc/articles/PMC7693838/ /pubmed/33147880 http://dx.doi.org/10.3390/toxins12110696 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lin, Ting-Yun Chou, Hsin-Hua Huang, Hsuan-Li Hung, Szu-Chun Indoxyl Sulfate and Incident Peripheral Artery Disease in Hemodialysis Patients |
title | Indoxyl Sulfate and Incident Peripheral Artery Disease in Hemodialysis Patients |
title_full | Indoxyl Sulfate and Incident Peripheral Artery Disease in Hemodialysis Patients |
title_fullStr | Indoxyl Sulfate and Incident Peripheral Artery Disease in Hemodialysis Patients |
title_full_unstemmed | Indoxyl Sulfate and Incident Peripheral Artery Disease in Hemodialysis Patients |
title_short | Indoxyl Sulfate and Incident Peripheral Artery Disease in Hemodialysis Patients |
title_sort | indoxyl sulfate and incident peripheral artery disease in hemodialysis patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693838/ https://www.ncbi.nlm.nih.gov/pubmed/33147880 http://dx.doi.org/10.3390/toxins12110696 |
work_keys_str_mv | AT lintingyun indoxylsulfateandincidentperipheralarterydiseaseinhemodialysispatients AT chouhsinhua indoxylsulfateandincidentperipheralarterydiseaseinhemodialysispatients AT huanghsuanli indoxylsulfateandincidentperipheralarterydiseaseinhemodialysispatients AT hungszuchun indoxylsulfateandincidentperipheralarterydiseaseinhemodialysispatients |